5.35
+0.07(+1.33%)
Currency In USD
Address
2200 Bridge Pkwy
Redwood City, CA 94065
United States of America
Phone
650 549 1400
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
January 10, 2020
| Name | Title | Pay | Year Born |
| Mr. Ronald A. Martell | President, Chief Executive Officer & Director | 1.04M | 1962 |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board & Director | 296,300 | 1957 |
| Mr. Jeetinder Singh Mahal M.B.A. | Chief Operating Officer | 667,628 | 1973 |
| Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer | 713,297 | 1972 |
| Ms. Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations | 0 | N/A |
| Mr. Matthew Ford | Vice President of Human Resources | 0 | N/A |
| Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research & Translational Medicine | 0 | N/A |
| Mr. David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy & Management | 0 | N/A |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.